← All trials
NCT03787082
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2019
- Primary completion
- Feb 28, 2021
- Completion date
- Feb 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PittsburghLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Institutes of Health (NIH)Collaborator
- University of PittsburghCollaborator
- University of PittsburghOverall official - principal investigator
- University of PittsburghReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.